Overview / Abstract: |
STATEMENT OF NEED An estimated 35,730 new cases of multiple myeloma are diagnosed in the United States annually, and 12,590 people die of the disease (Siegel et al, 2023). Characterized by clonal proliferation of malignant plasma cells in the bone marrow, multiple myeloma is associated with anemia, renal insufficiency, bone destruction, and hypercalcemia, all of which significantly impact patients’ quality of life. The development of novel therapies and combinations in recent years, including anti-CD38 antibodies, has provided numerous therapeutic options for newly diagnosed multiple myeloma. However, the optimal selection of induction therapy and subsequent treatment sequencing for individual patients remains a challenge. Additionally, factors including age, frailty, comorbidities, transplant eligibility, treatment-related toxicities, and supportive care needs complicate treatment decisions (Costello et al, 2022). This activity chaired by Urvi Shah, MD, Assistant Attending in the Myeloma Service at Memorial Sloan Kettering Cancer Center, will explore expert guidance on current standards and new directions in newly diagnosed multiple myeloma. TARGET AUDIENCE Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with multiple myeloma. LEARNING OBJECTIVES Upon completion of this activity, participants should be able to: Assess guideline-recommended treatment combination and sequencing strategies in NDMM |
Expiration |
Jul 05, 2024 |
Discipline(s) |
Physician CME, Physician Assistant CME |
Format |
Online, Webinar / Webcast / Video |
Credits / Hours |
1.25 CME |
Accreditation |
ACCME, ANCC |
Presenters / Authors / Faculty |
Urvi Shah, MD |
Sponsors / Supporters / Grant Providers |
Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. Supported by an educational grant from Sanofi. |
Keywords / Search Terms |
i3 Health i3 Health Oncology, i3 Health, CME, free CNE, Free CE, Free CME, MM, multiple myeloma, multiply relapsed, refractory, refractory multiple myeloma, therapeutics, treatment, therapies, patients, Free, CME, CE, hematologist, hematology, oncology, clinical data, therapy Free CE CME Free CE CME Free CE CME |